Investment area

Growth Investments



Date of investment

January 2023

Evosep is the leading platform offering a high-sample-throughput capability with excellent reproducibility (i.e., valuable, useable data) between sample runs and across instruments and sites. Evosep’s technology shapes the potential of proteomics by developing valuable applications, enabling widespread use, and the development of clinically meaningful protein-based diagnostics.

Visit site


Stephen van Helden


Departments: Growth Investments, Novo Holdings Equity US Inc., Bioindustrial Investments

Stephen joined Novo Holdings in 2022.

Prior to joining Novo Holdings, Stephen spent over 5 years developing new products, partnerships and businesses at The Production Board as an EIR, and Zymergen where he led many Industrial efforts including across Agriculture, Food and Packaging. He previously worked with McKinsey and Company as an Associate Partner across a number of sectors and geographies.

Stephen holds an MBA from Stanford University and a BSc in Electrical Engineering from the University of Cape Town.